Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
Quidel Corporation (NASDAQ: QDEL) announced its participation at the William Blair 41st Annual Growth Stock Conference on June 3, 2021. Presenting will be CEO Douglas Bryant and CFO Randy Steward at 10:40 a.m. Central time. The presentation will cover important business trends and developments. A live webcast and audio archive will be accessible via the company’s Investor Relations page. Quidel is a leader in rapid diagnostic solutions, aiming to enhance global healthcare quality.
Quidel Corporation (NASDAQ: QDEL) announces that its Sofia® SARS Antigen FIA has become the first rapid antigen test authorized by Health Canada for serial testing to detect active coronavirus infections in both symptomatic and asymptomatic individuals.
The test, which shows 96.7% agreement with PCR results within the first five days of symptoms, will be utilized every three days for asymptomatic individuals. This approval aims to enhance widespread screening in Canada, vital for controlling COVID-19 transmission and aiding economic recovery.
Quidel Corporation (QDEL) announces the availability of its QuickVue® At-Home OTC COVID-19 Test for online purchase on Amazon. This test allows consumers to self-administer a COVID-19 test and receive results in just 10 minutes. The product shows high accuracy, with positive agreement with PCR tests at 83.5% and negative agreement at 99.2%. A 2-pack is priced at $24.95 with free shipping. The test is available under FDA's Emergency Use Authorization but is not FDA approved.
Quidel Corporation (NASDAQ: QDEL) reported a remarkable 115% revenue increase to $375.3 million for Q1 2021, driven largely by COVID-19 related products, which generated $280.3 million. Net income surged by 340% to $178.1 million, translating to GAAP EPS of $4.09 per diluted share. Sales of Influenza products dropped to $5.2 million from $79.6 million year-on-year. The company received FDA EUAs for QuickVue® At-Home COVID-19 Tests, enhancing its portfolio for at-home testing. Gross profit rose 163% to $302.0 million.
Quidel Corporation (NASDAQ: QDEL) has partnered with Walgreens to distribute its QuickVue® At-Home OTC COVID-19 Test at 7,600 Walgreens stores across the U.S. and Puerto Rico. This collaboration enables consumers to purchase the test over-the-counter, enhancing accessibility. Each kit includes two tests and delivers results within 10 minutes, boasting an agreement rate of 83.5% for positive results with PCR tests. The QuickVue test is authorized under FDA's Emergency Use Authorization, vital in controlling COVID-19 spread.
Quidel Corporation (NASDAQ: QDEL) announced its participation in the virtual BofA Securities 2021 Health Care Conference on May 13, 2021. CEO Douglas Bryant and CFO Randy Steward will present at 2:00 p.m. ET, detailing business and financial trends. The presentation will include previously undisclosed material information. A live webcast and audio archive will be accessible via the Investor Relations section of Quidel’s website, with replays available for 14 days. Quidel is known for its rapid diagnostic testing solutions and innovative healthcare technologies.
Quidel is hosting a free webinar on May 5 to help healthcare providers differentiate between Lyme disease, COVID-19, and the flu. With Lyme disease affecting up to 400,000 Americans annually, accurate diagnosis is crucial, especially during peak tick season. Dr. Sean McCloy will lead the session, discussing the similarities in symptoms and highlighting the Sofia® 2 Lyme FIA test, which provides results in 15 minutes. This test enhances timely treatment, allowing physicians to act quickly based on patient needs.
Quidel Corporation (NASDAQ: QDEL) will announce its fiscal Q1 2021 financial results on May 6, 2021, after market close. CEO Douglas Bryant and CFO Randy Steward will host a conference call at 5:00 PM ET to discuss the results, business developments, and address questions. The company emphasizes that the call may include material undisclosed information. A live webcast will be available on their website, with replays accessible for one year and telephone replays for 14 days starting after the call.
Quidel Corporation (NASDAQ: QDEL) has finalized a distribution agreement with McKesson Corporation to enhance access to its QuickVue® At-Home OTC COVID-19 Test. This partnership aims to expedite the rollout to various markets, including schools and businesses. McKesson will leverage its retail and e-commerce platforms to facilitate the product's distribution. The QuickVue Test, authorized by the FDA, provides results in under 10 minutes and boasts high accuracy, agreeing with PCR results 83.5% of the time. Shipping is set to commence soon.
Quidel Corporation (QDEL) announced preliminary results for Q1 2021, projecting revenues between $374 million and $376 million, marking a 114% increase from $174.7 million in Q1 2020. COVID-19 test revenues are expected to exceed $280 million, a significant rise from $1 million last year. Despite strong performance in SARS tests, influenza product sales dropped to $5 million from $79.6 million due to an uncharacteristically low respiratory season. Gross margins are estimated at 80%, with earnings growth exceeding 300%. Further details are anticipated in their earnings call on May 6, 2021.